Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Ascites

Ascites

DefinitionAscites is the buildup of fluid inside the peritoneal cavity. It occurs when fluid moves out of the vascular system faster than the peritoneal lymphatics can remove it. This fluid shift is most commonly seen in liver cirrhosis but can also appear in several other systemic disorders.EtiologyCirrhosis remains the leading cause of ascites. Other conditions that can contribute include:Heart failureConstrictive pericarditisAbdominal cancersNephrotic syndromeSevere protein–calorie...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oligosaccharyltransferase Is Involved in Targeting to ER-Associated Degradation.

Cells·2025

Same author

Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2024

Same author

Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer.

Communications biology·2023

Same author

Upregulation of the ESCRT pathway and multivesicular bodies accelerates degradation of proteins associated with neurodegeneration.

Autophagy reports·2023

Same author

COP I and II dependent trafficking controls ER-associated degradation in mammalian cells.

iScience·2023

Same author

Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial.

Hepatology (Baltimore, Md.)·2023

Search research articles

Related Experiment Video

Updated: May 26, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosis.

Ron Benyair¹, Maria Kondratyev, Elena Veselkin

¹Department of Cell Research and Immunology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.

World Journal of Gastroenterology

|January 6, 2012

Summary

Researchers measured soluble H2a (sH2a) levels in human serum. Healthy individuals had consistent sH2a levels, while hepatitis C patients with cirrhosis showed significantly lower levels, suggesting diagnostic potential.

Keywords:

Asialoglycoprotein receptor Cirrhosis Hepatitis C virus Liver diagnosis Liver function

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Related Experiment Videos

Last Updated: May 26, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

Area of Science:

Biochemistry
Immunology
Hepatology

Background:

The asialoglycoprotein receptor (ASGPR) plays a role in liver function.
A soluble, secreted form of ASGPR (sH2a) presence in human serum is investigated.

Purpose of the Study:

To determine the existence and quantify sH2a levels in human serum.
To explore the potential diagnostic value of sH2a in liver disease.

Main Methods:

Developed a monoclonal antibody and an enzyme-linked immunosorbent assay (ELISA) for sH2a detection.
Measured sH2a concentrations in serum samples from healthy individuals and hepatitis C patients with cirrhosis.

Main Results:

Successfully produced recombinant sH2a and established a specific ELISA assay.
Healthy individuals exhibited stable sH2a serum levels (147 ± 19 ng/mL).
Hepatitis C patients with cirrhosis displayed significantly reduced sH2a levels (50 ± 9 ng/mL).

Conclusions:

Consistent sH2a levels in healthy individuals suggest constitutive secretion from hepatocytes.
Decreased sH2a levels in cirrhosis indicate potential as a biomarker for liver disease.